78. Drug Development and Alzheimer's Disease

  1. Alan J. Sinclair2,3,
  2. Dr John E. Morley4 and
  3. Professor Bruno Vellas5
  1. Julien Delrieu5,
  2. Antoine Piau1 and
  3. Professor Bruno Vellas5

Published Online: 12 MAR 2012

DOI: 10.1002/9781119952930.ch78

Pathy's Principles and Practice of Geriatric Medicine, Volume 1 & 2, Fifth Edition

Pathy's Principles and Practice of Geriatric Medicine, Volume 1 & 2, Fifth Edition

How to Cite

Delrieu, J., Piau, A. and Vellas, B. (2012) Drug Development and Alzheimer's Disease, in Pathy's Principles and Practice of Geriatric Medicine, Volume 1 & 2, Fifth Edition (eds A. J. Sinclair, J. E. Morley and B. Vellas), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119952930.ch78

Editor Information

  1. 2

    Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire, Luton, UK

  2. 3

    Institute of Diabetes for Older People (IDOP), Luton, UK

  3. 4

    Saint Louis University School of Medicine and St Louis Veterans' Affairs Medical Center, St Louis, MO, USA

  4. 5

    Gérontopôle, Toulouse University Hospital and INSERM Unit 558, University of Toulouse III, Toulouse, France

Author Information

  1. 1

    Gérontopôle, Toulouse University Hospital, Toulouse, France

  2. 5

    Gérontopôle, Toulouse University Hospital and INSERM Unit 558, University of Toulouse III, Toulouse, France

Publication History

  1. Published Online: 12 MAR 2012
  2. Published Print: 13 APR 2012

ISBN Information

Print ISBN: 9780470683934

Online ISBN: 9781119952930

SEARCH

Keywords:

  • Alzheimer's disease;
  • disease-modifying therapies;
  • clinical trials

Summary

The effects of current treatments for Alzheimer's disease (AD) are limited or controversial as they do not modify disease progression. Much effort is directed towards identifying disease-modifying therapies. Many clinical studies are ongoing with many new compounds, but still no disease-modifying drug is available. To explain the disappointing results of several randomized controlled trials, researchers have highlighted different errors, both in drug choice and in development programmes. According to the complexity of AD, it seems clear that multi-target therapies could be the future treatment approach.